Target intelligence / Profile preview

RNA-binding protein FXR2 (FXR2)

Target
FXR2
Molecular classification
RNA-binding protein, RNA metabolism regulator, Fragile X protein family, Other (not a classic drug target family like receptor or kinase)
01

Overview

FXR2 (RNA-binding protein FXR2) is a member of the Fragile X protein family and is encoded by the FXR2 gene on chromosome 17. It is an RNA-binding protein that helps regulate neuronal mRNA translation and synaptic function, acting alongside proteins such as FMRP and FXR1[1][2][4][5]. FXR2 is a structural component of Fragile X granules in the brain, where it is essential for proper granule formation and neuronal development[1]. Its functions in the brain include regulating mRNA stability, particularly for targets such as Noggin mRNA in hippocampal neurogenesis, formation of synaptic structures, and modulation of neuronal translation processes[2]. FXR2 interacts in protein complexes with FMRP and FXR1 and binds RNA through KH domains and an RGG box, conferring selectivity for specific nucleic acid structures[3][4]. Although not a direct drug target, FXR2's dysregulation is associated with neurodevelopmental and psychiatric phenotypes in animal models, partially overlapping with functions of FMRP, the protein deficient in Fragile X syndrome[2][4]. Note: FXR2 is *not* a classical therapeutic target like a receptor, enzyme, or transporter, and there are no approved drugs or mechanisms of action reported for direct FXR2 modulation. The protein is best classified as an RNA-binding protein critical for neuronal mRNA regulation and plasticity.

Other names
FXR2PFMR1 autosomal homolog 2FMR1L2RNA-binding protein FXR2FXR2
02

Biological functions

Regulation of mRNA translation and stabilityModulation of neuronal mRNA translationRegulation of synaptic plasticityRegulation of neurogenesis (especially in hippocampus)Formation of Fragile X granules (FXGs) in neuronsPresynaptic granule assemblyCircadian rhythm modulation
03

Disease associations

Neurodevelopmental disorders (implicated with fragile X mental retardation, but not proven causal in human disease)Neuropsychiatric disorders (through modulation of synaptic plasticity)Other (as a modulator via its interaction with FMR1/FXR1 family proteins)
04

Safety considerations

not a therapeutic target, so no drug safety profileknockout in mice affects neurogenesis, learning, and behavior

Beyond the preview

Go deeper on RNA-binding protein FXR2 (FXR2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on RNA-binding protein FXR2 (FXR2).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call